Page last updated: 2024-12-05

2-hydroxyisobutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-hydroxyisobutyric acid : A 2-hydroxy monocarboxylic acid that is isobutyric acid bearing a hydroxy substituent at position 2. It is a metabolite of methyl tertiary-butyl ether. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11671
CHEMBL ID1345148
CHEBI ID50129
SCHEMBL ID29373
MeSH IDM0051567

Synonyms (104)

Synonym
a-hydroxyisobutyric acid
ai3-31313
unii-dmw250u2hf
nsc 402158
lactic acid, 2-methyl-, l-
dmw250u2hf ,
nsc 4505
einecs 209-848-8
nsc4505
2-hydroxy-2-methylpropionic acid
2-hydroxyisobutyric acid
.alpha.-hydroxy-.alpha.-methylpropanoic acid
nsc-4505
.alpha.-hydroxyisobutanoic acid
propanoic acid, 2-hydroxy-2-methyl-
lactic acid, 2-methyl-
acetonic acid
hydroxydimethylacetic acid
2-hydroxy-2-methylpropanoic acid
2-methyllactic acid
.alpha.-hydroxyisobutyric acid
594-61-6
hiba
2-hydroxy-2-methylpropionsaeure
acido 2-hidroxi-2-metilpropionico
alpha-hydroxy-alpha-methylpropanoic acid
CHEBI:50129 ,
2-methyl-2-hydroxypropanoic acid
alpha-hydroxyisobutyric acid
alpha-hydroxyisobutanoic acid
acide 2-hydroxy-2-methylpropanoique
alpha-hydroxy-alpha-methylpropionic acid
2-methyl-2-hydroxypropionsaeure
nsc-402158
nsc402158
NCGC00090926-01
inchi=1/c4h8o3/c1-4(2,7)3(5)6/h7h,1-2h3,(h,5,6
alpha-hydroxyisobutyric acid, 99%
alpha-hydroxyisobutyric acid, 98%
H-6400
FT-0669843
M0360
AKOS001310472
A8360
NCGC00090926-02
LMFA01050417
2-hydroxy-2-methyl-propanoic acid
alpha-hydroxy-isobutyric acid
2-hydroxy-2-methyl-propionic acid
2-hydroxy-2-methylpropanoicacid
EN300-59285
NCGC00257677-01
cas-594-61-6
dtxsid4032954 ,
tox21_200123
dtxcid2012954
acetonate
alpha-hydroxyisobutanoate
alpha-hydroxyisobutyrate
alpha-hydroxy-alpha-methylpropanoate
FT-0612616
JC10155
S12287
S6307
SCHEMBL29373
AB00984267-01
methyl lactic acid [inci]
isobutyric acid, .alpha.-hydroxy-
methyl lactic acid
propanoic acid, 2-methyl-2-hydroxy-
(ch3)2cohcooh
alpha-hydroxy isobutyric acid
2-hydroxy-iso-butyric acid
2-hydroxy-isobutyric acid
hydroxyisobutyric acid
2-hydroxy isobutyric acid
2-hydroxyisobutyricacid
CHEMBL1345148
STR04462
C21297
mfcd00004459
2-hydroxy-2-methylpropionate
alpha-hydroxyisobutyric acid, purum, >=98.0% (hplc)
2-methyllactate
a-hydroxy-a-methylpropanoate
a-hydroxyisobutanoate
hydroxyisobutyrate
alpha-hib
a-hib
l-2-methyllactate
a-hydroxy-a-methylpropanoic acid
l-2-methyllactic acid
hydroxydimethylacetate
a-hydroxyisobutanoic acid
a-hydroxyisobutyrate
SY001526
2-hydroxy-2-methyl-d3-propionic-3,3,3-d3 acid
HY-W015924
Q2735617
CS-W016640
2-hydroxy-2-methyl propionic acid
alpha -hydroxyisobutyric acid
PD123991
Z220542620

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" We find that individual biomarker measurements are a valuable tool in reconstruction of previous exposures and that a simple pharmacokinetic model can identify the time frames over which an exogenous chemical and the related chemical biomarker are useful."( Exposure reconstruction for reducing uncertainty in risk assessment: example using MTBE biomarkers and a simple pharmacokinetic model.
Kim, D; Pleil, JD; Prah, JD; Rappaport, SM,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
2-hydroxy monocarboxylic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency1.99530.003245.467312,589.2998AID2517
AR proteinHomo sapiens (human)Potency42.13280.000221.22318,912.5098AID1259381; AID588515
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency35.48130.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency25.11890.001318.074339.8107AID926; AID938
retinoid X nuclear receptor alphaHomo sapiens (human)Potency19.42480.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency2.11570.000229.305416,493.5996AID743075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (7.69)18.7374
1990's9 (17.31)18.2507
2000's12 (23.08)29.6817
2010's22 (42.31)24.3611
2020's5 (9.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.31 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index58.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.85%)5.53%
Reviews4 (7.41%)6.00%
Case Studies1 (1.85%)4.05%
Observational0 (0.00%)0.25%
Other48 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]